Hubbard Stevan R
Skirball Institute of Biomolecular Medicine and Department of Pharmacology, New York University School of Medicine, New York 10016, USA.
Curr Opin Struct Biol. 2002 Dec;12(6):735-41. doi: 10.1016/s0959-440x(02)00383-4.
Receptor and non-receptor protein tyrosine kinases (PTKs) are essential enzymes in cellular signaling processes that regulate cell growth, differentiation, migration and metabolism. The kinase activity of PTKs is tightly controlled through steric, autoregulatory mechanisms, as well as by the action of protein tyrosine phosphatases. Recent structural studies have revealed several modes of autoregulation governing the catalytic state of these enzymes. Aberrant catalytic activity of many PTKs, via mutation or overexpression, plays an important role in numerous pathological conditions, including cancer. Structural studies of the Abl tyrosine kinase domain in complex with the small-molecule inhibitor STI571 provide a molecular basis for understanding the specificity determinants of this highly successful drug used in the treatment of chronic myeloid leukemia.
受体型和非受体型蛋白酪氨酸激酶(PTK)是细胞信号传导过程中的关键酶,可调节细胞生长、分化、迁移和代谢。PTK的激酶活性通过空间位阻、自动调节机制以及蛋白酪氨酸磷酸酶的作用受到严格控制。最近的结构研究揭示了几种控制这些酶催化状态的自动调节模式。许多PTK通过突变或过表达产生的异常催化活性在包括癌症在内的多种病理状况中起重要作用。与小分子抑制剂STI571复合的Abl酪氨酸激酶结构域的结构研究为理解这种用于治疗慢性粒细胞白血病的高度成功药物的特异性决定因素提供了分子基础。